Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.

Abstract: Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

Abstract: Bazedoxifene acetate formulations and compositions thereof having improved properties relating to reduction, elimination, or prevention of polymorphic conversion of bazedoxifene acetate, and processes for making such formulations and compositions. Components used in the formulations and compositions include a filler/diluent, an optional second filler/diluent, an optional antioxidant, a glidant/disintegrant, and a lubricant.

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Abstract: Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

Abstract: Methods for treatment of sexual dysfunction in men and women using combinations of phosphodiesterase (PDE) type 5 inhibitors and l-deprenyl or propargylamine compounds are described. Methods of reducing the dosage and preventing the side effects of PDE type 5 inhibitors are also described. The methods comprise administering a therapeutically effective amount of l-deprenyl or propargylamine compounds (also called monoamine oxidase [MAO] inhibitors) in combination with PDE inhibitors. Stimulation of nitric oxide production and vasodilation by l-deprenyl and propargylamine compounds augments the actions of PDE inhibitors or other drugs and methods used in the treatment of sexual dysfunction. The composition described here enhances the actions of PDE inhibitors primarily by increasing the generation of cyclic GMP by stimulating the nitric oxide pathway and secondarily by providing several additional benefits such as enhanced dopamine activity.

Abstract: A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.

Abstract: A pharmaceutical composition comprises uncoated particles of a single thermodynamic equilibrium reversed cubic phase material containing an active agent disposed within. The uncoated particles have an anionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent.

Abstract: A capsule for a powder has a body which is provided with an internal chamber (21) to hold the powder and first and second openings to an exterior environment. The body is adapted to be displaced from a filling state, in which the first and second openings are placed in fluid communication with one another through the internal chamber thereby enabling an airflow to be created through the body from the second opening to the first opening which is able to entrain powder in the exterior environment into the internal chamber for filling thereof, to a sealing state in which the internal chamber is sealed from the exterior environment so as to retain the powder held therein.

Abstract: Propellants comprising a combination of: (a) a liquid component that is soluble in the organic chemical-based material; (b) a soluble gas component that has a solubility of at least about 3% by weight in the organic chemical-based material; and, (c) a substantially insoluble gas component that has a solubility of less than about 3% by weight of the organic chemical-based material are effective for a wide range of airless applications. Adjustment of the ratios of (a) to (b) to (c) can lead to propellants that provide excellent spray patterns for a wide range of organic chemical-based formulations.

Abstract: A composition and method for simultaneously lightening and coloring hair. The composition generally consists of three components, specifically, a bleaching composition, an oxidizing composition and a dyeing composition. The composition preferably lightens hair color by a plurality of levels and simultaneously deposits tones that are attractive and long lasting. In a preferred embodiment, the bleaching composition is a powder composition based on silicate and/or carbonate salts and/or persulfate salts of ammonium, potassium or sodium. The persulfate bleaching composition can be ammonia-free, if desired. The oxidizing composition is preferably an anhydrous hydrogen peroxide solution, or another source of oxygen. The bleaching composition can be mixed with the oxidizing composition to form an anhydrous creme that is applied to the hair.

Abstract: Enteric film coating systems for orally ingestible substrates such as pharmaceutical tablets and dietary supplements are disclosed. In preferred aspects, the enteric film coatings include an ethylcellulose dispersion and a substantially gastro-insoluble pore former such as sodium alginate.

Abstract: Formulations and blends are described comprising zinc, silver, bismuth and copper in non-toxic amounts that are useful as treatments of a wide variety of conditions and diseases promoted by bacteria or other microorganisms.

Abstract: Compositions for treating anal and vaginal inflammations while maintaining normal vaginal floral activity utilizing magnesium and alkali metal salts at an acidic pH.

Abstract: The invention relates to a water-resistant mascara composition that has a high water content. The inventive mascara composition contains an oil phase comprising a liquid ester, an oil, or a mixture thereof, 1 to 50 percent by weight of a silicon-based film-forming agent, 1 to 10 percent by weight of a gel-forming agent selected among fatty acid esters, glycol derivatives, or mixtures thereof, 1 to 50 percent by weight of substances selected among pigments, powders, fillers, and mixtures thereof, an aqueous phase comprising 42 to 75 percent by weight of water, 0.1 to 10 percent by weight of a surfactant, and other carrier substances, auxiliary agents, active substances, or mixtures thereof until reaching 100 percent by weight. Said composition contains no wax and no hydrocarbon solvent.

Abstract: A topical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.

Abstract: A compound or groups of compounds, present in an active principle, derived from tunicates of the species Synoicum adareanum, as well as to pharmaceutical compositions comprising these compounds. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in the effective treatment of cancers, particularly malignant melanomas, colon cancer, and renal cancer cell lines.

Abstract: Novel ruthenium catalysts can be obtained by: i) treating a support material based on amorphous silicon dioxide one or more times with a halogen-free aqueous solution of a low molecular weight ruthenium compound and subsequently drying the treated support material at below 200° C., ii) reducing the solid obtained in i) by means of hydrogen at from 100 to 350° C., where step ii) is carried out directly after step i). These catalysts can be used for the catalytic hydrogenation of monosaccharides and disaccharides to produce sugar alcohols, with the exception of sorbitol.

Abstract: A process to reduce the temperature of a hydrogen and carbon monoxide containing gas by contacting the gas with a metal alloy surface having a lower temperature than the temperature of the gas, wherein the metal alloy surface has between 0 and 20 wt % iron, between 0 and 5 wt % aluminium, between 0 and 5 wt % silicon, between 20 and 50 wt % chromium and at least 35 wt % nickel, wherein the metal alloy surface maintains it lower temperature than the temperature of the gas by making use of coolant water.